SI-BONE, Inc. (NASDAQ:SIBN) Shares Purchased by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. grew its holdings in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 35.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 841,045 shares of the company’s stock after acquiring an additional 220,555 shares during the quarter. Harbor Capital Advisors Inc. owned about 2.01% of SI-BONE worth $11,791,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. FMR LLC raised its stake in shares of SI-BONE by 103.6% during the third quarter. FMR LLC now owns 2,354 shares of the company’s stock valued at $33,000 after purchasing an additional 1,198 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in SI-BONE during the 2nd quarter valued at about $61,000. Arizona State Retirement System raised its position in shares of SI-BONE by 9.0% during the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock worth $141,000 after buying an additional 903 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of SI-BONE during the 3rd quarter worth about $144,000. Finally, Deerfield Management Company L.P. Series C acquired a new stake in shares of SI-BONE in the 2nd quarter worth approximately $151,000. Institutional investors own 98.11% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Truist Financial lifted their price target on SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of SI-BONE in a report on Wednesday, November 20th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $23.00.

SI-BONE Stock Down 4.7 %

Shares of SI-BONE stock traded down $0.67 during midday trading on Friday, hitting $13.73. The company’s stock had a trading volume of 99,031 shares, compared to its average volume of 227,964. SI-BONE, Inc. has a 1-year low of $11.70 and a 1-year high of $21.64. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $575.81 million, a P/E ratio of -14.92 and a beta of 1.16. The stock has a 50-day simple moving average of $13.67 and a 200-day simple moving average of $14.17.

Insiders Place Their Bets

In related news, insider Anthony J. Recupero sold 3,670 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total value of $51,013.00. Following the completion of the sale, the insider now owns 222,814 shares of the company’s stock, valued at approximately $3,097,114.60. The trade was a 1.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Anshul Maheshwari sold 2,439 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $12.68, for a total transaction of $30,926.52. Following the transaction, the chief financial officer now directly owns 194,623 shares in the company, valued at approximately $2,467,819.64. The trade was a 1.24 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,348 shares of company stock worth $356,349. 3.90% of the stock is currently owned by company insiders.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.